Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we get some optimism from the new director of the National Cancer Institute, despite a brain drain playing out in the industry and stagnant funding numbers. Also, advocates press the federal government to encourage manufacturing for the prostate cancer drug Xtandi.
Advocates press government to exercise march-in rights for Xtandi
Advocates are pressing the Biden administration to license patents for Xtandi, a prostate cancer treatment, to other manufacturers so that lower-cost versions become available. In a letter to CMS, they said that two different federal laws — including march-in rights — would allow the U.S. government to authorize “qualified companies” to make and sell generic versions of the blockbuster drug.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect